Glasgow, United Kingdom
Mironid® Limited, founded in 2015 and based in the United Kingdom, is making noteworthy advancements in the biotechnology sector. This innovative drug discovery company is pioneering the development of proprietary drug candidate molecules through the modulation of key cell signaling proteins. This unique approach is opening doors across multiple therapeutic areas, with a keen focus on rare genetic kidney diseases.
Recently, Mironid® Limited secured a £30.70M Series A investment on 13 September 2023. This important investment round was driven by a robust consortium of investors, including Sofinnova Partners, BioGeneration Ventures, Scottish Enterprise, EIF, Epidarex Capital, Roche Venture Fund, and the University of Strathclyde. This substantial financial backing reflects strong confidence in the company's unique drug discovery platform and its potential to significantly impact the healthcare landscape.
